Research ExplorerPublicationsComplete Epstein-Barr virus seropositivity in a large cohort...

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

Standard

Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. / Abrahamyan, Sargis; Eberspächer, Bettina; Hoshi, Muna-Miriam; Aly, Lilian; Luessi, Felix; Groppa, Sergiu; Klotz, Luisa; Meuth, Sven G; Schroeder, Christoph; Grüter, Thomas; Tackenberg, Björn; Paul, Friedemann; Then-Bergh, Florian; Kümpfel, Tania; Weber, Frank; Stangel, Martin; Bayas, Antonios; Wildemann, Brigitte; Heesen, Christoph; Zettl, Uwe; Warnke, Clemens; Antony, Gisela; Hessler, Nicole; Wiendl, Heinz; Bittner, Stefan; Hemmer, Bernhard; Gold, Ralf; Salmen, Anke; Ruprecht, Klemens; German Competence Network Multiple Sclerosis (KKNMS).

In: J NEUROL NEUROSUR PS, Vol. 91, No. 7, 07.2020, p. 681-686.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Abrahamyan, S, Eberspächer, B, Hoshi, M-M, Aly, L, Luessi, F, Groppa, S, Klotz, L, Meuth, SG, Schroeder, C, Grüter, T, Tackenberg, B, Paul, F, Then-Bergh, F, Kümpfel, T, Weber, F, Stangel, M, Bayas, A, Wildemann, B, Heesen, C, Zettl, U, Warnke, C, Antony, G, Hessler, N, Wiendl, H, Bittner, S, Hemmer, B, Gold, R, Salmen, A, Ruprecht, K & German Competence Network Multiple Sclerosis (KKNMS) 2020, 'Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis', J NEUROL NEUROSUR PS, vol. 91, no. 7, pp. 681-686. https://doi.org/10.1136/jnnp-2020-322941

APA

Abrahamyan, S., Eberspächer, B., Hoshi, M-M., Aly, L., Luessi, F., Groppa, S., Klotz, L., Meuth, S. G., Schroeder, C., Grüter, T., Tackenberg, B., Paul, F., Then-Bergh, F., Kümpfel, T., Weber, F., Stangel, M., Bayas, A., Wildemann, B., Heesen, C., ... German Competence Network Multiple Sclerosis (KKNMS) (2020). Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J NEUROL NEUROSUR PS, 91(7), 681-686. https://doi.org/10.1136/jnnp-2020-322941

Vancouver

Abrahamyan S, Eberspächer B, Hoshi M-M, Aly L, Luessi F, Groppa S et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J NEUROL NEUROSUR PS. 2020 Jul;91(7):681-686. https://doi.org/10.1136/jnnp-2020-322941

Bibtex

@article{a81c8a95d5af4415a6a578c0ecd6ae33,
title = "Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis",
abstract = "OBJECTIVE: To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS).METHODS: Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing-remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we retrospectively analysed the EBV seroprevalence across different age cohorts, ranging from 0 to >80 years, in a large hospital population (N=16 163) from Berlin/Northern Germany.RESULTS: EBNA-1 antibodies were detected by CLIA in 839 of 901 patients with CIS/RRMS. Of the 62 patients without EBNA-1 antibodies, 45 had antibodies to VCA as detected by CLIA. In all of the remaining 17 patients, antibodies to EBV were detected by immunoblot. Altogether, 901 of 901 (100%) patients with CIS/RRMS were EBV-seropositive. EBV seropositivity increased with age in the hospital population but did not reach 100% in any of the investigated age cohorts.CONCLUSION: The complete EBV seropositivity in this large cohort of patients with early MS strengthens the evidence for a role of EBV in MS. It also suggests that a negative EBV serology in patients with suspected inflammatory central nervous system disease should alert clinicians to consider diagnoses other than MS.",
author = "Sargis Abrahamyan and Bettina Ebersp{\"a}cher and Muna-Miriam Hoshi and Lilian Aly and Felix Luessi and Sergiu Groppa and Luisa Klotz and Meuth, {Sven G} and Christoph Schroeder and Thomas Gr{\"u}ter and Bj{\"o}rn Tackenberg and Friedemann Paul and Florian Then-Bergh and Tania K{\"u}mpfel and Frank Weber and Martin Stangel and Antonios Bayas and Brigitte Wildemann and Christoph Heesen and Uwe Zettl and Clemens Warnke and Gisela Antony and Nicole Hessler and Heinz Wiendl and Stefan Bittner and Bernhard Hemmer and Ralf Gold and Anke Salmen and Klemens Ruprecht and {German Competence Network Multiple Sclerosis (KKNMS)}",
note = "{\textcopyright} Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = jul,
doi = "10.1136/jnnp-2020-322941",
language = "English",
volume = "91",
pages = "681--686",
journal = "J NEUROL NEUROSUR PS",
issn = "0022-3050",
publisher = "BMJ PUBLISHING GROUP",
number = "7",

}

RIS

TY - JOUR

T1 - Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis

AU - Abrahamyan, Sargis

AU - Eberspächer, Bettina

AU - Hoshi, Muna-Miriam

AU - Aly, Lilian

AU - Luessi, Felix

AU - Groppa, Sergiu

AU - Klotz, Luisa

AU - Meuth, Sven G

AU - Schroeder, Christoph

AU - Grüter, Thomas

AU - Tackenberg, Björn

AU - Paul, Friedemann

AU - Then-Bergh, Florian

AU - Kümpfel, Tania

AU - Weber, Frank

AU - Stangel, Martin

AU - Bayas, Antonios

AU - Wildemann, Brigitte

AU - Heesen, Christoph

AU - Zettl, Uwe

AU - Warnke, Clemens

AU - Antony, Gisela

AU - Hessler, Nicole

AU - Wiendl, Heinz

AU - Bittner, Stefan

AU - Hemmer, Bernhard

AU - Gold, Ralf

AU - Salmen, Anke

AU - Ruprecht, Klemens

AU - German Competence Network Multiple Sclerosis (KKNMS)

N1 - © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/7

Y1 - 2020/7

N2 - OBJECTIVE: To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS).METHODS: Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing-remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we retrospectively analysed the EBV seroprevalence across different age cohorts, ranging from 0 to >80 years, in a large hospital population (N=16 163) from Berlin/Northern Germany.RESULTS: EBNA-1 antibodies were detected by CLIA in 839 of 901 patients with CIS/RRMS. Of the 62 patients without EBNA-1 antibodies, 45 had antibodies to VCA as detected by CLIA. In all of the remaining 17 patients, antibodies to EBV were detected by immunoblot. Altogether, 901 of 901 (100%) patients with CIS/RRMS were EBV-seropositive. EBV seropositivity increased with age in the hospital population but did not reach 100% in any of the investigated age cohorts.CONCLUSION: The complete EBV seropositivity in this large cohort of patients with early MS strengthens the evidence for a role of EBV in MS. It also suggests that a negative EBV serology in patients with suspected inflammatory central nervous system disease should alert clinicians to consider diagnoses other than MS.

AB - OBJECTIVE: To determine the prevalence of antibodies to Epstein-Barr virus (EBV) in a large cohort of patients with early multiple sclerosis (MS).METHODS: Serum samples were collected from 901 patients with a clinically isolated syndrome (CIS) or early relapsing-remitting multiple sclerosis (RRMS) participating in the German National MS cohort, a prospective cohort of patients with early MS with stringent inclusion criteria. Epstein-Barr nuclear antigen (EBNA)-1 and viral capsid antigen (VCA) antibodies were measured in diluted sera by chemiluminescence immunoassays (CLIAs). Sera of EBNA-1 and VCA antibody-negative patients were retested undiluted by an EBV IgG immunoblot. For comparison, we retrospectively analysed the EBV seroprevalence across different age cohorts, ranging from 0 to >80 years, in a large hospital population (N=16 163) from Berlin/Northern Germany.RESULTS: EBNA-1 antibodies were detected by CLIA in 839 of 901 patients with CIS/RRMS. Of the 62 patients without EBNA-1 antibodies, 45 had antibodies to VCA as detected by CLIA. In all of the remaining 17 patients, antibodies to EBV were detected by immunoblot. Altogether, 901 of 901 (100%) patients with CIS/RRMS were EBV-seropositive. EBV seropositivity increased with age in the hospital population but did not reach 100% in any of the investigated age cohorts.CONCLUSION: The complete EBV seropositivity in this large cohort of patients with early MS strengthens the evidence for a role of EBV in MS. It also suggests that a negative EBV serology in patients with suspected inflammatory central nervous system disease should alert clinicians to consider diagnoses other than MS.

U2 - 10.1136/jnnp-2020-322941

DO - 10.1136/jnnp-2020-322941

M3 - SCORING: Journal article

C2 - 32371533

VL - 91

SP - 681

EP - 686

JO - J NEUROL NEUROSUR PS

JF - J NEUROL NEUROSUR PS

SN - 0022-3050

IS - 7

ER -